Vesicoureteral reflux

Hyaluronic Acid Raw Material Market Forecasted to Reach USD 10.8 Billion by 2030 with Notable CAGR of 6.5% - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 28, 2023
Chemicals, Plastics, Manufacturing, Woman, Wound healing, Filler (linguistics), Osteoarthritis, Incidence, USD, International Society, Smith & Nephew, Ophthalmology, Vesicoureteral reflux, Elective surgery, Toxicity, Growth, Medical tourism, Administration, Hyaluronic acid, Salix Pharmaceuticals, Fine chemical

The "Hyaluronic Acid Raw Material Market Size, Share & Trends Analysis Report By Application (Ophthalmology, Orthopedics), By Source (Non-Animal, Animal), By Grade, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hyaluronic Acid Raw Material Market Size, Share & Trends Analysis Report By Application (Ophthalmology, Orthopedics), By Source (Non-Animal, Animal), By Grade, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global hyaluronic acid raw material market size is expected to reach USD 10.8 billion by 2030.
  • The market is expected to expand at a CAGR of 6.5% from 2023 to 2030.
  • Furthermore, the drug delivery segment is projected to be the fastest growing over the forecast period with a significantly higher CAGR.

Teleflex Completes Acquisition of Palette Life Sciences

Retrieved on: 
Tuesday, October 10, 2023
NYSE, Acquisition, EPS, Rectum, Vesicoureteral reflux, Radiation, Teleflex, Fecal incontinence, TFX, Prostate cancer, Palette

WAYNE, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of Palette Life Sciences AB.

Key Points: 
  • WAYNE, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of Palette Life Sciences AB.
  • The acquisition adds Barrigel®, a biodegradable sculptable rectal spacer, to Teleflex’s Interventional Urology portfolio.
  • On July 26, Teleflex announced its entry into a definitive agreement to acquire Palette.
  • The acquisition is expected to be approximately $0.25 dilutive to adjusted earnings per share (excluding non-recurring purchase accounting items and other acquisition and integration related costs) in 2023.

Palette Life Sciences Enters Into Definitive Agreement with Teleflex Incorporated

Retrieved on: 
Wednesday, July 26, 2023
Teleflex, Marketing, Culture, Ole Mikkelsen, Food and Drug Administration, Incontinence, Hyaluronic acid, TFX, Vesicoureteral reflux, Acquisition, Rectum, Patient, Science, Wilson Sonsini Goodrich & Rosati, FDA, Guggenheim Partners, NYSE, Food, Prostate cancer, Pharmaceutical industry, Nursing

SANTA BARBARA, Calif. and STOCKHOLM, Sweden, July 26, 2023 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully-integrated global life sciences company dedicated to improving patient outcomes, today announced it has entered into a definitive agreement to be acquired by Teleflex Incorporated (NYSE:TFX), for an upfront cash payment of $600 million at closing, and up to an additional $50 million upon the achievement of certain commercial milestones. The acquisition is subject to customary closing conditions, including receipt of certain regulatory approvals, and is expected to be completed in the fourth quarter of 2023.

Key Points: 
  • The acquisition solidifies plans for the global commercial expansion of the Palette Life Sciences portfolio of Non-Animal Stabilized Hyaluronic Acid (NASHA)-based products, including Barrigel®, Deflux® and Solesta®.
  • “The original founding vision for Palette Life Sciences was to disrupt the rectal spacing market with a new product innovation that would serve as a better option for doctors and their patients,” said Travis Gay, Chief Commercial Officer and co-Founder of Palette Life Sciences.
  • “We are extremely excited to add Palette Life Sciences products into Teleflex’s Interventional Urology portfolio,” said James Leech, Chief Business Officer of Palette Life Sciences.
  • Per Langoe, Chief Executive Officer and co-Founder of Palette Life Sciences said, “Teleflex is an excellent fit for our products and team.

Teleflex to Acquire Palette Life Sciences

Retrieved on: 
Wednesday, July 26, 2023
Marketing, TRUS, TFX, Fecal incontinence, LRP, Incidence, Vesicoureteral reflux, Acquisition, Rectum, Patient safety, Urology, Growth, FDA, Health, Hand, NYSE, Prostate cancer, Pharmaceutical industry, Medical imaging, Teleflex

Palette Life Sciences is estimated to generate net sales of approximately $56 million, on a standalone basis, in 2023.

Key Points: 
  • Palette Life Sciences is estimated to generate net sales of approximately $56 million, on a standalone basis, in 2023.
  • “The acquisition of Palette Life Sciences will allow us to incorporate this exciting technology into our Interventional Urology business unit and bring urologists, radiation oncologists, and other specialists more innovative technologies that can positively impact patient care.
  • We believe Palette Life Sciences will be a meaningful contributor to our growth in the coming years.
  • The Palette Life Sciences portfolio also includes Deflux® and Solesta®, which are NASHA based tissue bulking agents designed to treat pediatric vesicoureteral reflux and fecal incontinence, respectively.

Georgia Urology's Pediatric Specialists Receive Top-10 Ranking in U.S. News & World Report

Retrieved on: 
Monday, July 17, 2023
U.S. News & World Report Best Hospitals Rankings, Pediatrics, Hospital, Urination, Incontinence, Woman, Infertility, Laparoscopy, Multimedia, Urinary tract infection, Child, Birth, Radiology, Pediatric urology, VUR, MRU, U.S. News & World Report, Vesicoureteral reflux, Patient, Urology, Physician, Help, Children's Healthcare of Atlanta, Kidney, Diagnosis, CHOA, News, Nursing, Dentistry

ATLANTA, July 17, 2023 /PRNewswire/ -- Georgia Urology's pediatric urologists are among the medical professionals recognized in U.S. News & World Report's 2023-2024 Best Children's Hospitals rankings. This annual honor spotlights excellence in pediatric healthcare.

Key Points: 
  • The practice's wholly owned subsidiary, Georgia Urology Pediatrics, collaborates with and provides pediatric urological services at Children's Healthcare of Atlanta (CHOA), an acclaimed pediatric hospital system, which occupies a top-10 spot in the magazine's Best Hospitals for Pediatric Urology category.
  • "This honor continues to make Georgia Urology Pediatrics the only top-ranked private practice in the country," says Dr. Andrew Kirsch, a practicing pediatric urologist and Georgia Urology's medical director.
  • You can schedule an appointment with Georgia Urology and Georgia Urology Pediatrics conveniently online.
  • Georgia Urology is the largest urology practice in Georgia with more than 25 locations and seven ambulatory surgery centers across metro Atlanta.

Hyaluronic Acid Global Market Report 2022: Growing Awareness for Antiaging Products Driving Sector Forward - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022
Cosmetics, Retail, Hyaluronic acid, Obesity, Income, Osteoarthritis, Industry, Prevalence, Cosmetic, WHO, MEA, CAGR, Adoption, COVID-19, Ageing, Growth, Stent, Conditional sentence, USD, Vesicoureteral reflux, Joint, Patient, Dry eye syndrome, Diabetes, Population, Awareness, EU

The global hyaluronic acid market size is expected to reach USD 16.8 billion by 2030, expanding at a CAGR of 7.45%, according to this report.

Key Points: 
  • The global hyaluronic acid market size is expected to reach USD 16.8 billion by 2030, expanding at a CAGR of 7.45%, according to this report.
  • The industry is evolving rapidly due to the increasing adoption of aesthetic procedures in developed and developing regions.
  • The increasing the use of hyaluronic acid surfaces in cardiovascular implants, such as stents and vascular grafts, for improving the compatibility coupled with the growing awareness about anti-aging products is fueling the growth.
  • The growing geriatric population in China and Japan provide a large customer base for anti-aging products and services.

Palette Life Sciences Announces the Establishment of a Wholly Owned Subsidiary in Japan

Retrieved on: 
Tuesday, February 15, 2022
List of life sciences, Patient, Education, Radiation, GLOBE, VUR, Physician, General manager, Urology, Organization, Medicine, Interior design, LATAM, Vesicoureteral reflux

SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced the establishment of a wholly owned subsidiary located in Tokyo, Japan to commercialize Palette’s portfolio of medical products. As of January 1, 2022, Palette Life Sciences Japan K.K. has been cleared to distribute Deflux® directly to customers throughout the country. In addition, Palette Life Sciences is working to expand its Japanese offering, actively pursuing regulatory clearance for its Barrigel® and Solesta® brands.

Key Points: 
  • SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced the establishment of a wholly owned subsidiary located in Tokyo, Japan to commercialize Palettes portfolio of medical products.
  • In addition, Palette Life Sciences is working to expand its Japanese offering, actively pursuing regulatory clearance for its Barrigel and Solesta brands.
  • Prior to establishing the subsidiary, Palette Life Sciences partnered with local distributors in Japan to provide access to Deflux.
  • It will also connect Japan with global resources to provide consistent training and educational support, said Yoshiki Kawabata, General Manager, Palette Life Sciences Japan.

Global Hyaluronic Acid Market Forecasts 2021-2028: Growing Preference for Short-Treatment Regimens and High Prevalence of Target Diseases - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 6, 2022
Men, General Health, Consumer, Fitness & Nutrition, Cosmetics, Retail, Surgery, Chemicals, Plastics, Women, Seniors, Health, Physical Therapy, Manufacturing, COVID-19, Dry eye syndrome, CAGR, Growth, Hyaluronic acid, Patient, Prevalence, Arthralgia, Obesity, Osteoarthritis, Awareness, Ageing, Diabetes, Conditional sentence, USD, Population, Stent, Adoption, Vesicoureteral reflux, WHO, Joint, Cosmetic, Pharmaceutical industry

The global hyaluronic acid market size is expected to reach USD 14.4 billion by 2028, expanding at a CAGR of 7.19%.

Key Points: 
  • The global hyaluronic acid market size is expected to reach USD 14.4 billion by 2028, expanding at a CAGR of 7.19%.
  • Factors such as increasing concern of population regarding chemicals, desire to get quick and evident results, and shorter recovery time, are high impact rendering drivers for this market.
  • The market is evolving rapidly due to the increasing adoption of aesthetic procedures in developed and developing regions.
  • Increasing the use of hyaluronic acid surfaces in cardiovascular implants, such as stents and vascular grafts, for improving the compatibility coupled with growing awareness about anti-aging products is fueling the growth.

Palette Life Sciences Launches Newly Branded Website Featuring United States Portfolio

Retrieved on: 
Thursday, September 16, 2021
Health, Food, Vesicoureteral reflux, Urine, Urology, US Foods, FDA, Kidney, Prostate cancer, IUD, Patient, Sneeze, Â, Incontinence, Fecal incontinence, CE, Radiation, Adult, VUR, Diet, GLOBE, Infection, SUI, Time-invariant system, Sale, Woman, Hyaluronic acid, Exercise, Interior design, Medicine, Fine chemical, Pharmaceutical industry

SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today launched its newly renovated Palettelifesciences.com website.

Key Points: 
  • SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences , a fully integrated global life sciences company dedicated to improving patient outcomes, today launched its newly renovated Palettelifesciences.com website.
  • Palette is proud of our best-in-class product portfolio that brings hope to those with unmet medical needs, said Per G. Lang, Chief Executive Officer and Board Director of Palette Life Sciences.
  • By obtaining rights to NASHA technologies, Palette Life Sciences has the ability to both produce and leverage a portfolio of products that are adaptable, customizable and flexible, said Travis Gay, Chief Commercial Officer of Palette Life Sciences.
  • Palette Life Sciences is a fully integrated life sciences company.

U.S. Department of Energy’s National Nuclear Security Administration Awards NorthStar Medical Radioisotopes $37 Million in Cooperative Agreement Funds to Further Domestic Molybdenum-99 (Mo-99) Production

Retrieved on: 
Monday, August 30, 2021
Hospitals, Biotechnology, Energy, Nuclear, Radiology, Health, Pharmaceutical, Other Science, Science, Industry, Weapon, Company, Vesicoureteral reflux, University of Missouri Research Reactor Center, Isotopes of molybdenum, U.S. Department of Energy, Office of Inspector General, Pregnancy, Degenerative disease, LLC, University, Congress, Cancer, Nuclear medicine, Method, Physician, DOE, Uranium, System, Food, Doctor of Philosophy, NNSA, Child, Injection, USP, Cystography, Senior, U.S. Department of Defense Strategy for Operating in Cyberspace, Radiation exposure, Safety, Radiopharmacology, Nose, U.S. Navy Diving Manual, Risk, Patient, Technetium, Rash, Radiopharmaceutical, Radiation, Funding opportunity announcement, Sodium, FDA, Sodium pertechnetate, Allergy, Anaphylaxis, Water, Google Images, HEU, NorthStar, Regulation of tobacco by the U.S. Food and Drug Administration, Pharmaceutical industry, Vaccine, Medical imaging, Birth control, Palladium, DOE/NNSA, the RadioGenix® System (Technetium Tc- 99m Generator), NorthStar Medical Radioisotopes, LLC (NorthStar), DOE/NNSA, THE RADIOGENIX® SYSTEM (TECHNETIUM TC- 99M GENERATOR), NORTHSTAR MEDICAL RADIOISOTOPES, LLC (NORTHSTAR)

NorthStar deeply appreciates these new cooperative agreement awards and this financial and technical support provided by DOE/NNSA, said Stephen Merrick, President and Chief Executive Officer.

Key Points: 
  • NorthStar deeply appreciates these new cooperative agreement awards and this financial and technical support provided by DOE/NNSA, said Stephen Merrick, President and Chief Executive Officer.
  • We are proud to be the first and only company to achieve commercialized Mo-99 production through collaboration with DOE/NNSA to date.
  • We are working aggressively to ensure sustainable domestic Mo-99 supply through dual production and processing hubs for additional capacity and scheduling flexibility.
  • With inclusion of the current and past awards, NorthStar has been awarded a total of over $100 million in cooperative agreement funds by DOE/NNSA.